Laurie Olson Biography and Net Worth

Insider of Pfizer

Laurie J. Olson serves as Director of the Company. Ms. Olson is a seasoned pharmaceutical executive with more than 30 years of commercial and corporate strategy experience, most recently serving as the Executive Vice President, Strategy and Commercial Operations at Pfizer Inc. until 2018. In this role, Ms. Olson led a global organization accountable for corporate strategic planning, portfolio management, and commercial support functions. Ms. Olson served as a member of Pfizer's Portfolio Strategy and Investment Committee as well as the Pfizer Board of Directors' Science and Technology Committee, where she was accountable for informing therapeutic area strategies and the utilization of new technologies and analytic methods to drive R&D and commercial productivity. She also was a member of the Business Development, Disclosure, Diversity, and Compliance Committees where she supported Pfizer's commitment to maintaining its transparency and compliance with internal and external stakeholders. Prior to her role as Executive Vice President, Ms. Olson held various positions of increasing authority during her tenure at Pfizer from 1987 to 2018. She currently serves as a member of the Board of Trustees of the Mystic Seaport Museum in Mystic, Connecticut. Ms. Olson received a B.A. in Economics from State University of New York at Stony Brook and an M.B.A. in Marketing from Hofstra University.

What is Laurie J. Olson's net worth?: The estimated net worth of Laurie J. Olson is at least $389,940.42 as of April 1st, 2024. Ms. Olson owns 15,238 shares of Pfizer stock worth more than $389,940 as of December 3rd. This net worth approximation does not reflect any other assets that Ms. Olson may own. Learn More about Laurie J. Olson's net worth.
How do I contact Laurie J. Olson?: The corporate mailing address for Ms. Olson and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Laurie J. Olson's contact information.
Has Laurie J. Olson been buying or selling shares of Pfizer?: Laurie J. Olson has not been actively trading shares of Pfizer within the last three months. Most recently, Laurie J. Olson sold 10,214 shares of the business's stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a transaction totalling $418,774.00. Following the completion of the sale, the insider now directly owns 72,672 shares of the company's stock, valued at $2,979,552. Learn More on Laurie J. Olson's trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 2 times. They purchased a total of 4,000 shares worth more than $107,650.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 10/30/2024.

Laurie J. Olson Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/13/2018	Sell	10,214	$41.00	$418,774.00	72,672
6/6/2018	Sell	19,000	$36.45	$692,550.00	98,644
8/21/2017	Sell	8,064	$32.70	$263,692.80	74,506
5/11/2016	Sell	4,700	$33.50	$157,450.00	71,659
6/11/2015	Sell	26,000	$34.39	$894,140.00
6/12/2014	Sell	36,275	$29.53	$1,071,200.75

Laurie J. Olson Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $25.59

$25.54

$25.90

50 Day Range

MA: $27.83

$24.80

$30.20

2 Week Range

Now: $25.59

$24.48

$31.54

Volume

20,218,198 shs

Average Volume

38,369,387 shs

Market Capitalization

$145.02 billion

P/E Ratio

34.58

Dividend Yield

6.41%

Beta

0.65

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.